利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

22 条记录 (耗时 0.023 秒)

    TREATMENT OF NEURODEGENERATIVE DISEASES BY THE USE OF GPR49
    1.
    发明授权
    TREATMENT OF NEURODEGENERATIVE DISEASES BY THE USE OF GPR49 有权
    治疗GPR49的神经退行性疾病

    公开(公告)号：EP1713501B1

    公开(公告)日：2008-01-16

    申请号：EP04803345.0

    申请日：2004-11-29

    申请人： CELLZOME AG

    发明人： HOPF, Carsten ,  DREWES, Gerard ,  RUFFNER, Heinz

    IPC分类号： A61K39/00

    CPC分类号： C07K16/28 ,  A61K31/7088 ,  C07K2317/82

    摘要： The invention relates to the use of a GPR49-interacting molecule for the preparation of a pharmaceutical composition for the treatment of a neurogenerative disease. Hereby s the GPR49-interacting molecule is preferably an inhibitor of GPR49 and particularly it has the capacity to modulate the activity of gamma-secretase and/or beta-secretase. Furthermore the invention concerns a process for identifying a gamma-secretase and/or a beta-secretase modulator, comprising the following steps: a. identifying of a GPR49-interacting molecule by determining whether a given test compound is a GPR49-interacting molecule, b. determining whether the GPR49-interacting molecule of step a) is capable of modulating gamma-secretase and/or beta-secretase activity.

    RAPAMYCIN DERIVATIVES FOR TREATING NEUROBLASTOMA
    2.
    发明公开
    RAPAMYCIN DERIVATIVES FOR TREATING NEUROBLASTOMA 有权
    用于鉴定LRRK2相互作用的分子以及用于清洁LRRK2

    公开(公告)号：EP1866433A1

    公开(公告)日：2007-12-19

    申请号：EP07717962.0

    申请日：2007-03-13

    申请人： CELLZOME AG

    发明人： DREWES, Gerard ,  HOPF, Carsten ,  READER, Valerie

    IPC分类号： C12Q1/48 ,  G01N33/68 ,  C12N9/12

    CPC分类号： C12Q1/485 ,  G01N2800/2835

    摘要： The invention provides in a first aspect a method for the identification of an LRRK2 interacting compound, comprising the steps of providing a protein preparation containing LRRK2, contacting the protein preparation with indol ligand 91 immobilized on a solid support under conditions allowing the formation of an indol ligand 91-LRRK2 complex, incubating the indol ligand 91-LRRK2 complex with a given compound, and determining whether the compound is able to separate LRRK2 from the immobilized indol ligand 91. Furthermore, the invention relates to a method for the identification of an LRRK2 interacting compound, comprising the steps of providing a protein preparation containing LRRK2, contacting the protein preparation with indol ligand 91 immobilized on a solid support and with a given compound under conditions allowing the formation of an indol ligand 91-LRRK2 complex, and detecting the indol ligand 91-LRRK2 complex. Additionally, the invention provides a method for the identification of an LRRK2 interacting compound, comprising the steps of providing two aliquots of a protein preparation containing LRRK2, contacting one aliquot with indol ligand 91 immobilized on a solid support under conditions allowing the formation of an indol ligand 91-LRRK2 complex, contacting the other aliquot with indol ligand 91 immobilized on a solid support and with a given compound under conditions allowing the formation of an indol ligand 91- LRRK2 complex, and determining the amount of indol ligand 91-LRRK2 complex. Furthermore, the invention relates to a method for the purification of LRRK2, comprising the steps of providing a protein preparation containing LRRK2, contacting the protein preparation with indol ligand 91 immobilized on a solid support under conditions allowing the formation of an indol ligand 91-LRRK2 complex, and separating LRRK2 from the immobilized indol ligand 91.